| Year |
Citation |
Score |
| 2018 |
Garcia NK, Deperalta G, Wecksler AT. Current Trends in Biotherapeutic Higher Order Structure Characterization by Irreversible Covalent Footprinting Mass Spectrometry. Protein and Peptide Letters. PMID 30484396 DOI: 10.2174/0929866526666181128141953 |
0.313 |
|
| 2018 |
Lin M, Krawitz D, Callahan MD, Deperalta G, Wecksler AT. Characterization of ELISA Antibody-Antigen Interaction using Footprinting-Mass Spectrometry and Negative Staining Transmission Electron Microscopy. Journal of the American Society For Mass Spectrometry. PMID 29512051 DOI: 10.1007/S13361-017-1883-9 |
0.302 |
|
| 2018 |
Wecksler AT, Yin J, Lee Tao P, Kabakoff B, Sreedhara A, Deperalta G. Photo-Disruption of the Structurally Conserved Cys-Cys-Trp Triads Leads to Reduction-Resistant Scrambled Intrachain Disulfides in an IgG1 Monoclonal Antibody. Molecular Pharmaceutics. PMID 29502420 DOI: 10.1021/Acs.Molpharmaceut.7B01128 |
0.321 |
|
| 2017 |
Zhang Y, Wecksler AT, Molina P, Deperalta G, Gross ML. Mapping the Binding Interface of VEGF and a Monoclonal Antibody Fab-1 Fragment with Fast Photochemical Oxidation of Proteins (FPOP) and Mass Spectrometry. Journal of the American Society For Mass Spectrometry. PMID 28255747 DOI: 10.1007/S13361-017-1601-7 |
0.319 |
|
| 2015 |
Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY. Inhibition of mutant Kras(G12D) -initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. Cancer Letters. PMID 26683769 DOI: 10.1016/J.Canlet.2015.11.042 |
0.318 |
|
| 2015 |
Wecksler AT, Kalo MS, Deperalta G. Mapping of Fab-1:VEGF Interface Using Carboxyl Group Footprinting Mass Spectrometry. Journal of the American Society For Mass Spectrometry. PMID 26419770 DOI: 10.1007/S13361-015-1273-0 |
0.308 |
|
| 2015 |
Kaur P, Tomechko SE, Kiselar J, Shi W, Deperalta G, Wecksler AT, Gokulrangan G, Ling V, Chance MR. Characterizing monoclonal antibody structure by carboxyl group footprinting. Mabs. 7: 540-52. PMID 25933350 DOI: 10.1080/19420862.2015.1023683 |
0.355 |
|
| 2015 |
Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemotherapy and Pharmacology. 75: 161-71. PMID 25413440 DOI: 10.1007/S00280-014-2626-2 |
0.306 |
|
| 2014 |
Kaur P, Tomechko S, Kiselar J, Shi W, Deperalta G, Wecksler AT, Gokulrangan G, Ling V, Chance MR. Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. Mabs. 6: 1486-99. PMID 25484052 DOI: 10.4161/19420862.2014.975096 |
0.343 |
|
| 2014 |
Morisseau C, Wecksler AT, Deng C, Dong H, Yang J, Lee KS, Kodani SD, Hammock BD. Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation. Journal of Lipid Research. 55: 1131-1138. PMID 24771868 DOI: 10.1194/Jlr.M049718 |
0.365 |
|
| 2014 |
Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL, Gomes AV, Baar K, Weiss RH, Hammock BD. Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anti-Cancer Drugs. 25: 433-46. PMID 24525589 DOI: 10.1097/Cad.0000000000000079 |
0.308 |
|
| 2014 |
Liao J, Zhang W, Hwng SH, Li H, Wecksler AT, Ma K, Hammock BD, Yang G. Abstract 1250: Inhibition of pancreatic carcinogenesis by t-CUPM, a dual inhibitor of c-Raf and soluble epoxide hydrolase Cancer Research. 74: 1250-1250. DOI: 10.1158/1538-7445.Am2014-1250 |
0.309 |
|
| 2013 |
Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 3732-7. PMID 23726028 DOI: 10.1016/J.Bmcl.2013.05.011 |
0.313 |
|
| 2011 |
Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. Journal of Medicinal Chemistry. 54: 3037-50. PMID 21434686 DOI: 10.1021/Jm2001376 |
0.307 |
|
| 2009 |
Wecksler AT, Garcia NK, Holman TR. Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1 Bioorganic and Medicinal Chemistry. 17: 6534-6539. PMID 19716306 DOI: 10.1016/J.Bmc.2009.08.005 |
0.586 |
|
| 2009 |
Wecksler AT, Kenyon V, Garcia NK, Deschamps JD, Van Der Donk WA, Holman TR. Kinetic and structural investigations of the allosteric site in human epithelial 15-lipoxygenase-2 Biochemistry. 48: 8721-8730. PMID 19645454 DOI: 10.1021/Bi9009242 |
0.612 |
|
| 2009 |
Wecksler AT, Jacquot C, Van Der Donk WA, Holman TR. Mechanistic investigations of human reticulocyte 15- and platelet 12-lipoxygenases with arachidonic acid Biochemistry. 48: 6259-6267. PMID 19469483 DOI: 10.1021/Bi802332J |
0.6 |
|
| 2008 |
Wecksler AT, Kenyon V, Deschamps JD, Holman TR. Substrate specificity changes for human reticulocyte and epithelial 15-lipoxygenases reveal allosteric product regulation Biochemistry. 47: 7364-7375. PMID 18570379 DOI: 10.1021/Bi800550N |
0.599 |
|
| 2008 |
Jacquot C, Wecksler AT, McGinley CM, Segraves EN, Holman TR, van der Donk WA. Isotope sensitive branching and kinetic isotope effects in the reaction of deuterated arachidonic acids with human 12- and 15-lipoxygenases. Biochemistry. 47: 7295-303. PMID 18547056 DOI: 10.1021/Bi800308Q |
0.586 |
|
| 2007 |
Neidig ML, Wecksler AT, Schenk G, Holman TR, Solomon EI. Kinetic and spectroscopic studies of N694C lipoxygenase: A probe of the substrate activation mechanism of a nonheme ferric enzyme Journal of the American Chemical Society. 129: 7531-7537. PMID 17523638 DOI: 10.1021/Ja068503D |
0.594 |
|
| 2006 |
Segraves EN, Chruszcz M, Neidig ML, Ruddat V, Zhou J, Wecksler AT, Minor W, Solomon EI, Holman TR. Kinetic, spectroscopic, and structural investigations of the soybean lipoxygenase-1 first-coordination sphere mutant, Asn694Gly Biochemistry. 45: 10233-10242. PMID 16922498 DOI: 10.1021/Bi060577E |
0.566 |
|
| Show low-probability matches. |